Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

All amounts are in U.S. dollars

QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and six-month periods ended June 30, 2009.

    Second Quarter 2009 Highlights

    April

    - Two poster presentations at the American Association of Cancer
      Research ("AACR") Annual Meeting on in vitro and in vivo results for
      AEZS-126 in human tumors, and one poster presentation on Phase 1
      results with AEZS-112 in solid tumors or lymphoma.

    - Notification from Nasdaq that the Company had regained compliance
      with Nasdaq's minimum bid price rules.

    May

    - Presentation at the American Society of Clinical Oncology ("ASCO")
      Annual Meeting of results supporting evaluation of AEZS-108 in
      prostate cancer.

    June

    - Presentation at the ASCO Annual Meeting of positive Phase 2 data on
      perifosine in advanced metastatic colon cancer and advanced renal cell
      carcinoma by the Company's partner, Keryx Biopharmaceuticals, Inc.

    - Acquisition from Ardana Bioscience Ltd. of all assets relating to
      AEZS-130.

    - Disclosure of neutral results for the Company's Phase 2 trial in
      non-small cell lung cancer with perifosine as radioenhancer.

    - Announcement of the initiation of the extension of the Company's North
      American Phase 3 efficacy study with cetrorelix in benign prostatic
      hyperplasia ("BPH"). This extension of the study is sponsored by
      sanofi-aventis, the Company's partner for the US market.

    - Poster presentation at the Endocrine Society ("ENDO") Annual Meeting
      on AEZS-130 as a simple diagnostic test for 
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... London, UK (PRWEB) July 10, 2014 ... inaugural 21st Century Medicine Forum on ‘Commercialising Longevity ... scientists and entrepreneurs to the London Bioscience Innovation ... Biogerontology Research Foundation and Aging Analytics Ltd. The ... and investment in translational research for age-related disease, ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... produced by plants and bacteria pose a significant threat to ... toxin in Germany. Now, new research published on July 21st ... a clearer view of the combination of similar and divergent ... cell. Ricin is a highly toxic protein derived from ...
... the potential for bioterrorism isn,t just about the U.S., ... bacteria, a virus or a toxin could happen anywhere, ... paper aimed at prevention. "Any emerging country that ... to be aware of the potential for bioterrorism," said ...
... nature for their muse, researchers have used a common protein ... energy-storing hydrogen gas. The synthetic material works 10 times faster ... report in the August 12 issue of the journal ... every second. This step is just one part ...
Cached Biology Technology:Targeting toxin trafficking 2Global bioterrorism threat analyzed for world animal health office 2Catalyst that makes hydrogen gas breaks speed record 2Catalyst that makes hydrogen gas breaks speed record 3Catalyst that makes hydrogen gas breaks speed record 4
(Date:7/14/2014)... to the discovery and description of Rhipidocyrtus muiri ... turned out to represent a new genus and species. The ... from Borneo is discussed in a recent paper published in ... The holotype male, and only known specimen of Rhipidocyrtus ... subsequent to this it was transferred among several researchers in ...
(Date:7/14/2014)... T-cell activation and differentiation by regulating the expression ... to guarantee immunological tolerance and prevents immune responses ... to autoimmune disease. Roquin is thus an immune ... per cent of the population. They usually occur ... a genetic predisposition exists. Only in rare cases ...
(Date:7/14/2014)... maize farmers selected for genes that improved the harvesting ... use ,doubles, of their genomes reveals. The findings could ... Oxford University researchers captured a ,genetic snapshot, of maize ... plant made a double of its genome a ... evolved to use these ,copied, genes to cope with ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2A-maize-ing double life of a genome 2
... This press release is available in French . ... in children is now beginning to be elucidated. Acute lymphoblastic leukemia ... higher risk of having a relapse when treated with E. ... leukemia. This is what a study by Dr. Maja Krajinovic published ...
... The VTT Technical Research Centre of Finland and the ... a new research center in Berkeley, California. The opening ... keynote speech was given by Dr. Sydney Brenner - ... The new VTT/MSI Center for Bioengineering will focus ...
... melting even when temperatures don,t hit record highs, according to ... the Department of Earth and Atmospheric Sciences at The City ... could undergo a self-amplifying cycle of melting and warming that ... even if you don,t have record-breaking highs, as long as ...
Cached Biology News:Gene responsible for relapses in young leukemia patients 2Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
... versatile Promega Flipper® Racks are ideal for ... small tubes. These polypropylene racks withstand extreme ... freezer storage. They may also be autoclaved ... is two-sided; one side accommodates 0.5ml microcentrifuge ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Biology Products: